All In Biotech

Drug Trial Radar · NCT06846710

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of HS-20118 in Adult Participants

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 2, 2025

Primary completion

Jul 14, 2026

Study completion Jul 14, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Conditions

  • Psoriasis

Interventions

  • HS-20118Drug

    Single and multiple ascending doses of HS-20118 orally

  • HS-20118 placeboOther

    Single and multiple ascending doses of HS-20118-matched placebo orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  2. Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  3. Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  4. Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
  5. Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Kinetic Clinical Research

    Anaheim, California

  • Clinitiative - Floridian Clinical Research, LLC

    Miami Lakes, Florida

  • NuLine Clinical Trial Center (Network)

    Pompano Beach, Florida

  • Pacific Clinical Research Network (PCRN), Auckland

    Takapuna, Auckland, New Zealand

  • Pacific Clinical Research Network (PCRN), Christchurch

    Christchurch, Christchurch, New Zealand

  • Momentum Clinical Research, Dunedin

    Dunedin, Dunedin, New Zealand

  • Momentum Clinical Research, Pukekohe

    Pukekohe, Pukekohe, New Zealand

  • Pacific Clinical Research Network (PCRN), Wellington

    Upper Hutt, Upper Hutt, New Zealand

  • Momentum Clinical Research, Wellington

    Mount Cook, Wellington Region, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.